A 5x jump in debt looks like a red flag — until you see what it paid for.
When Torrent Pharmaceuticals’ debt rose to ₹14,798 Cr, above its annual revenue, it read like a warning sign on interest burden. But the number needs context.
Strategic leverage: the debt didn’t come from operational strain — it funded the high-margin acquisition of JB Chemicals to expand market share.
Cash flow engine: as the chronic portfolio integrates, rising operating cash flows plus a planned QIP are set to bring debt metrics down by FY28.
Proven playbook: Torrent has a track record of using debt aggressively for accretive M&A, then paying it down fast on strong domestic cash generation.
Near-term interest coverage is worth tracking, but the underlying business looks healthy enough to absorb, service and eventually eliminate the leverage.